The majority of the epigenomic reports in hepatocellular carcinoma have focused on identifying novel differentially methylated drivers or passengers of the oncogenic process. Few reports have considered the technologies in place for clinical translation of newly identified biomarkers. The aim of this study was to identify epigenomic technologies that need only a small number of samples to discriminate HCC from non-HCC tissue, a basic requirement for biomarker development trials. To assess that potential, we used quantitative Methylation Specific PCR, oligonucleotide tiling arrays, and Methylation BeadChip assays. Concurrent global DNA hypomethylation, gene-specific hypermethylation, and chromatin alterations were observed as a hallmark of HCC. A global loss of promoter methylation was observed in HCC with the Illumina BeadChip assays and the Nimblegen oligonucleotide arrays. HCC samples had lower median methylation peak scores and a reduced number of significant promoter-wide methylated probes. Promoter hypermethylation of \textit{RASSFIA}, \textit{SSBP2}, and \textit{B4GALT1} quantified by qMSP had a sensitivity ranging from 38\% to 52\%, a specificity of 100\%, and an AUC from 0.58 to 0.75. A panel combining these genes with HCC risk factors had a sensitivity of 87\%, a specificity of 100\%, and an AUC of 0.91.

1. Introduction

Promoter-wide alterations of DNA methylation have been described at all stages that encompass hepatocarcinogenesis, precancerous lesions, and tumor initiation to unresectable HCC [1, 2], mostly focusing on aberrant hypermethylation of CpG islands in gene promoter regions near the Transcription Start Site (TSS) [3, 4]. Several hypermethylated genes have been identified using a range of diverse technologies. On the other hand, studies are also reporting promoter hypomethylation in specific genes to play an important role in HCC [5, 6], suggesting that high frequencies of hypomethylation, in various cancers, would be valuable as a cancer diagnostic marker.

The earlier methylation studies of HCC used the candidate gene approach and first generation methylation
microarrays, which study less than 7K CpG islands [7]. A recent number of studies have used Methylated DNA immunoprecipitation–on–chip analysis (MeDIP–chip) [8] and BeadChip assay technologies to identify novel genes differentially methylated in HCC [9]. Most HCC methylation studies have used available technologies to profile and identify differentially methylated genes that drive the oncogenic process [10].

The contribution of DNA methylation to the development of HCC is not yet elucidated. A methylation study in HCC is also challenging as there are several well-known risk factors for HCC, such as alcohol-induced cirrhosis and chronic viral hepatitis B or C infection [11]. Aberrant DNA methylation profiles across the genome were identified in tumor tissues from US HCC cases that are predominantly related to HCV infection [12]. Yet not much emphasis has been placed on using existing methylation platforms to evaluate differentially methylated genes as biomarkers of HCC, regardless of whether these alterations are driving the oncogenic process or are molecular changes that occur during malignant transformation.

We selected two existing methylation platforms to separately distinguish between HCC and non–HCC liver tissue in a small number of samples: an oligonucleotide methylation tiling array (MeDIP–chip, Nimblegen’s 385K Promoter, and CpG Island methylation array) and the Infinium Human Methylation 27K BeadChip assay (Illumina). We then generated a list of hypermethylated genes based on both the frequency in which the genes had been identified as methylated in different studies and also in the methylation arrays we used. From this list, we chose three genes for validation using existing methylation platforms to evaluate differentially methylated genes as biomarkers of HCC, regardless of whether these alterations are driving the oncogenic process or are molecular changes that occur during malignant transformation.

2. Materials and Methods

2.1. Patient Selection. Deidentified frozen primary HCC, adjacent nontumor (cirrhotic and noncirrhotic), and normal liver (noncirrhotic tissue obtained from autopsies) tissue samples were obtained from the Johns Hopkins University School of Medicine and the Human Cooperative Tissue Network. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Johns Hopkins Institutional Review Board. All patients had not undergone therapy prior to sample collection. The samples were frozen in liquid nitrogen and stored at −80°C.

2.2. DNA Extraction, Bisulfite Conversion, and MeDIP Enrichment. Tissue samples were digested with 1% SDS and 50 μg/mL proteinase K (Bushranger Mannheim) at 48°C overnight, followed by phenol/chloroform extraction and ethanol precipitation of DNA as previously described [13]. Prior to using qMSP and the Illumina BeadChip assay, bisulfite modification of 2 μg of genomic DNA was performed as previously described [14]. Prior to using the Nimblegen tiling arrays, 500 ng of genomic DNA was sheared using a water bath sonicator (Bioruptor UCD-200, Diagenode). Sonicated DNA was then analyzed on a 1.5% agarose gel to ensure that it had an optimal size of 200–1000 bp. MeDIP was subsequently performed with the Methyl DNA Immunoprecipitation Kit (Epigenex). Fractions of Input DNA and Immunoprecipitated DNA from each sample were subsequently sent to Nimblegen for labeling, hybridization, and scanning.

2.3. Illumina BeadChip Array. Bisulfite-treated DNA from 3 HCC samples and 3 adjacent normal liver samples was hybridized to the Human Methylation 27K BeadChip, which quantitatively interrogates 27,578 CpG loci covering more than 14,000 genes at single-nucleotide resolution. The Infinum Methylation assay detects cytosine methylation at CpG islands based on highly multiplexed genotyping of bisulfite-converted genomic DNA (gDNA). The assay interrogates these chemically differentiated loci using two site-specific probes, one designed for the methylated locus (M bead type) and another for the unmethylated locus (U bead type). Single-base extension of the probes incorporates a labeled ddNTP, which is subsequently stained with a fluorescence reagent. The level of methylation for the interrogated locus can be determined by calculating the ratio of the fluorescent signals from the methylated versus unmethylated sites.

2.4. Nimblegen 385K CpG Island Plus Promoter Array. DNA (500 ng) from 3 liver tissue samples (1HCC and 2 non–cirrhotic normal liver samples) enriched with MeDIP were hybridized to Nimblegen Promoter plus CpG Island 385K oligonucleotide tiling arrays. A single array design covers 28,226 CpG islands and promoter regions for 17,000 RefSeq genes. The promoter region covered is 1 kb long: 800 bp upstream from the TSS and 200 bp downstream from the TSS. Small CpG islands are extended at both ends for a total additional coverage of 700 bp for more reliable detection. DNA methylation positive control regions, such as the HoxA gene cluster, H19/IGF2 cluster, KCNQ1 cluster, and IGF2R gene, are also included on the array.

2.5. Spotfire Analysis and Heat map Creation. The beta values of all probes on the Illumina Infinium arrays were subjected to log10 transformation in order to generate a dendrogram and corresponding heat map based on unsupervised hierarchical clustering with Spotfire (Somerville, MA). The clustering was performed with the unweighted average method using correlation as the similarity measure and ordering by average values.

2.6. Bioinformatics Analysis of Methylation Array Data. The Microarray Core at Johns Hopkins School of Medicine performed the bioinformatics analysis of the Infinium array data using Illumina’s proprietary BeadStudio software package.
to provide average methylation Beta values for each probe. Nimblegen performed the bioinformatics analysis for the 385K CpG Island Plus Promoter Array. Nimblegen uses the ACME algorithm to identify hypermethylated genes that have a statistically significant methylation peak score above 2 [15].

2.7. Gene Selection from Public Databases of Known Methylation Events in Cancer. Candidate gene selection for promoter methylation analysis was performed utilizing existing databases of known methylation events in cancer [16, 17]. We generated a list of hypermethylated genes based on both the frequency in which the genes had been identified as methylated in different studies and also in the methylation arrays we used. From this list, we chose three genes for validation in an independent cohort comprised of HCC and adjacent nonpathological samples using quantitative Methylation-Specific PCR (qMSP). qMSP primers and probes span an 800 bp region upstream from the TSS. The genes chosen were sequence-specific single-stranded DNA-binding protein 2 (SSBP2), which has been previously shown to be hypermethylated in other solid tumors [18], beta-1,4-galactosyltransferase-1 (B4GALT1), not previously shown to be hypermethylated in cancer, and the Ras association domain family member 1 (RASSFIA), already shown to be hypermethylated in HCC [10].

2.8. Quantitative Methylation-Specific PCR. DNA from 27 HCC and 22 adjacent normal tissue samples (cirrhotic, noncirrhotic, and cryptogenic) was bisulfite treated and analyzed with qMSP. Fluorogenic PCR reactions were carried out in a reaction volume of 20 μL consisting of 600 nmol/L of each primer, 200 μmol/L probe, 0.75 units platinum Taq polymerase (Invitrogen), 200 μmol/L of each dATP, dCTP, dGTP, and dTTP, 200 nmol/L ROX dye reference (Invitrogen), 16.6 mmol/L ammonium sulfate, 67 mmol/L Trizma (Sigma, St. Louis, MO), 6.7 mmol/L magnesium chloride, 10 mmol/L mercaptoethanol, and 0.1% DMSO. Duplicates of three microliters (3 μL) of bisulfite-modified DNA solution were used in each real-time methylation-specific PCR (qMSP) amplification reaction. Primers and probes were designed to specifically amplify the promoters of the three genes of interest (RASSFIA, SSBP2, and B4GALT1) and the promoter of a reference gene, actin-B (ACTB). Primer and probe sequences and annealing temperatures are provided in Supplementary Table 1 in Supplementary Material available online at http://dx.doi.org/10.1155/2014/597164.

Amplification reactions were carried out in 384-well plates in a 7900 HT Fast Real-Time PCR System (Applied Biosystems) and were analyzed by SDS 2.2.1 Sequence Detector System (Applied Biosystems). Thermal cycling was initiated with a first denaturation step at 95°C for 3 minutes, followed by 40 cycles of 95°C for 15 seconds, and 58°C for 1 minute. Each plate included patient DNA samples, positive (Bisulfite-converted Universal Methylated Human DNA Standard, Zyko Research) and negative (normal leukocyte DNA or DNA from a known unmethylated cell line) controls, and multiple water blanks. Serial dilutions (60 ng, 6 ng, 0.6 ng, 0.06 ng, and 0.006 ng) of Bisulfite-converted Universal Methylated Human DNA Standard were used to construct a standard curve for each gene.

2.9. Statistical Analysis for qMSP and Methylation Array Data. qMSP values were adjusted for DNA input by expressing results as ratios between 2 absolute measurements. The relative level of methylated DNA for each gene in each sample was determined as a ratio of qMSP for the amplified gene to ACTB and then multiplied by 100 for easier tabulation (average DNA quantity of methylated gene of interest/average DNA quantity for internal reference gene b-actin) × 100) [19]. The samples were categorized as unmethylated or methylated based on detection of methylation above a threshold set for each gene. For quality control, all amplification curves were visualized and scored without knowledge of the clinical data. ROC curves were used to identify a cut-off ratio above the highest control ratio observed for each gene to set specificity at 100% [10]. Hypermethylation ratios for each gene were compared between cancer HCC and non-HCC samples. Once the best individually discriminating genes were found, 2-gene and 3-gene panels were tested to identify the highest sensitivity with specificity set at 100% for each gene.

3. Results

Patient characteristics are summarized in Table 1 (note that, for some samples analyzed by qMSP, clinical information was missing and only patients’ histology was known). The majority (58%) of the patients in our study were men. The mean age of the patients was 47.3 years, and most (56%) of the patients were over 50 years old. The ethnicities of the patients in our study were White (74%), Black (23%), and Asian (2%). The most frequent HCC risk factor seen in the patients of this study was viral infection with HCV (35%) or HBV (5%). Interestingly, cryptogenic cirrhosis was seen in 26% of the patients. Alcohol intake was the risk factor for a handful of patients (5%). "M" represents that a sample has a value above the qMSP methylation threshold for that gene. This sample is methylated. "U" represent that a sample has a value below the qMSP methylation threshold for that gene. This sample is not methylated.

3.1. Global and Gene-Specific Differential DNA Promoter Methylation Arrays. We used scatterplots to compare differential DNA methylation values between HCC and normal liver tissue samples hybridized to the 385K Nimblegen tiling array after DNA enrichment with MeDIP (MeDIP-chip). Figure 1 shows representative scatterplots and histograms in which a decrease in global DNA promoter methylation clearly distinguishes between HCC and normal tissue. Scatterplots and histograms of genome-wide DNA methylation array data provide a snapshot of the differences in methylation patterns between tumor and normal samples. Genome-wide hypomethylation was observed in the tumors when compared to normal samples. A representative tumor sample has less significant methylated probes (1,503) than either one of the normal liver tissue samples (2,585 and 2,887, resp.). Furthermore, the median methylation score was significantly
| ID | Age | Sex | Race | Type  | Etiology | Histology | Size | AFP | B4GALT1 | RASSF1A | SSBP2 |
|----|-----|-----|------|-------|----------|-----------|------|-----|----------|---------|-------|
| 16 | 53  | M   | W    | Normal| Cryptogenic| Cirrhosis | -    | -   | U        | U       | U     |
| 22 | 58  | M   | W    | Normal| HCV      | Cirrhosis | -    | -   | U        | U       | U     |
| 30 | 65  | M   | W    | Normal| HCV      | Cirrhosis | -    | -   | U        | U       | U     |
| 31 | 67  | M   | W    | Normal| HCV      | Cirrhosis | -    | -   | U        | M       | M     |
| 21 | 58  | M   | W    | Normal| Other    | Cirrhosis | -    | -   | U        | U       | U     |
| 15 | 50  | F   | B    | Normal| Cryptogenic| Noncirrhotic | -    | -   | U        | U       | U     |
| 2  | 19  | F   | B    | Normal| HCV      | Noncirrhotic | -    | -   | U        | U       | M     |
| 29 | 62  | F   | W    | Normal| HCV      | Noncirrhotic | -    | -   | U        | U       | U     |
| 9  | 40  | F   | B    | Normal| Other    | Noncirrhotic | -    | -   | U        | U       | U     |
| 4  | 26  | F   | W    | Normal| Other    | Noncirrhotic | -    | -   | U        | U       | M     |
| 13 | 45  | F   | W    | Normal| Other    | Noncirrhotic | -    | -   | U        | U       | U     |
| 35 | 81  | F   | W    | Normal| Other    | Noncirrhotic | -    | -   | U        | M       | U     |
| 18 | 54  | M   | B    | Normal| Cryptogenic| Noncirrhotic | -    | -   | U        | U       | U     |
| 10 | 42  | M   | W    | Normal| Other    | Noncirrhotic | -    | -   | U        | M       | U     |
| 20 | 55  | M   | W    | Normal| Other    | Noncirrhotic | -    | -   | U        | M       | M     |
| 36 | unk | unk | unk  | Normal| unk      | unk       | -    | -   | U        | U       | M     |
| 37 | unk | unk | unk  | Normal| unk      | unk       | -    | -   | U        | U       | U     |
| 38 | unk | unk | unk  | Normal| unk      | unk       | -    | -   | U        | U       | M     |
| 39 | 53  | M   | M    | Normal| ETOH    | Noncirrhotic | -    | -   | U        | U       | U     |
| 40 | 19  | F   | F    | Normal| HCV      | Noncirrhotic | -    | -   | U        | U       | U     |
| 41 | 57  | M   | M    | Normal| HCV      | Cirrhosis | -    | -   | U        | U       | U     |
| 42 | 60  | M   | M    | Normal| HCV      | Cirrhosis | -    | -   | U        | U       | U     |
| 5  | 28  | F   | W    | Tumor | Other    | HCC      | 2.5  | 1   | M        | U       | U     |
| 28 | 62  | F   | W    | Tumor | HCV      | HCC      | 2.8  | 17  | M        | M       | M     |
| 17 | 53  | M   | W    | Tumor | Cryptogenic| HCC      | 4    | 10  | U        | M       | U     |
| 7  | 40  | F   | B    | Tumor | Other    | HCC      | 3.7  | 1   | U        | U       | M     |
| 25 | 59  | F   | AS   | Tumor | HBV      | HCC      | 4    | 20  | M        | M       | M     |
| 3  | 20  | F   | W    | Tumor | HCV      | HCC      | 4    | unk | U        | U       | U     |
| 27 | 60  | M   | B    | Tumor | HCV/ETOH | HCC      | 4    | 20  | M        | M       | M     |
| 11 | 45  | M   | W    | Tumor | HCV      | HCC      | 5.0  | unk | M        | M       | M     |
| 8  | 40  | M   | W    | Tumor | HCV      | HCC      | 5.5  | 1110 | U        | U       | U     |
| 32 | 67  | M   | W    | Tumor | HCV      | HCC      | 6    | 2   | M        | M       | M     |
| 33 | 73  | M   | W    | Tumor | Other    | HCC      | 6    | 2   | U        | M       | M     |
| 6  | 37  | M   | B    | Tumor | Other    | HCC      | 7.0  | 54071 | U        | M       | U     |
| 23 | 58  | M   | W    | Tumor | Other    | HCC      | 7.2  | 4659 | M        | U       | M     |
| 14 | 50  | F   | B    | Tumor | Cryptogenic| HCC      | 9    | 1594 | U        | M       | U     |
| 26 | 60  | M   | W    | Tumor | Cryptogenic| HCC      | 12   | 146  | M        | M       | M     |
| 19 | 55  | M   | W    | Tumor | Other    | HCC      | 17   | 5   | U        | M       | M     |
| 12 | 45  | F   | B    | Tumor | HVB/HCV | HCC      | unk  | unk | U        | U       | U     |
| 24 | 58  | M   | W    | Tumor | HCV      | HCC      | unk  | unk | M        | M       | M     |
| 1  | 19  | F   | B    | Tumor | HCV      | HCC      | 25   | 19764 | U        | M       | M     |
| 34 | 74  | F   | W    | Tumor | Cryptogenic| HCC      | 4.5  | unk | M        | M       | M     |
| 43 | 42  | M   | M    | Tumor | Other    | HCC      | 15   | NA  | M        | M       | U     |
| 44 | 26  | F   | M    | Tumor | Other    | HCC      | 8    | NA  | M        | M       | U     |
| 45 | 12  | F   | M    | Tumor | Other    | HCC      | NA   | NA  | M        | M       | U     |
| 46 | NA  | NA  | NA   | Tumor | NA       | HCC      | NA   | NA  | U        | M       | U     |
| 47 | NA  | NA  | NA   | Tumor | NA       | HCC      | NA   | NA  | U        | M       | M     |
| 48 | NA  | NA  | NA   | Tumor | NA       | HCC      | NA   | NA  | U        | U       | M     |
| 49 | 45  | F   | F    | Tumor | Cryptogenic| HCC      | 1.5  | NA  | M        | M       | M     |

M: Methylated; U: Unmethylated; unk: unknown.
lower for the tumor sample (5.7) than for the normal samples (6.7).

We used unsupervised clustering of the Illumina BeadChip array results to create a heat map based on correlation, which clearly separates the three HCC samples from the adjacent normal liver sample (Figure 2). Please note that, for one normal sample, even though it clustered with the other two adjacent normal samples, probe-specific methylation levels were higher than expected.

3.2. Promoter Hypermethylation in Tumor and Adjacent Normal Samples. Our search of publicly available methylation databases found a combined total of 549 methylated genes when searching for hepatocellular carcinoma (389) and hepatoma (160), 451 of which were unique genes. After crossing that list with the list of frequently methylated genes we identified using methylation arrays, we chose three genes for validation, one gene that was already found to be hypermethylated in HCC by several groups (RASSF1A) and two genes that we had reported as methylated in other tumors but not in HCC (B4GALT1 and SSBP2). We quantified the promoter methylation of these 3 genes in 27 HCC samples and 22 adjacent normal samples. To determine the frequency of methylation, we used primers and probes for qMSP previously designed in our laboratory based on bisulfite sequencing data [20, 21].

RASSF1A was methylated in 14/27 (52%) of HCC samples and in 1/17 (6%) of adjacent normal samples. B4GALT1 was methylated in 14/27 (52%) of HCC samples and in 0/20 (0%) of adjacent normal samples. SSBP2 was methylated in 14/27 (52%) of HCC samples and in 6/18 (33%) of adjacent normal samples. Most of the HCC samples (78%) had at least one of these three genes methylated, while less than half of the adjacent normal samples (44%) had one gene methylated. Methylation of at least two of these genes was observed in 70% of the HCC samples and in 0% of the adjacent normal samples (Figures 3(a)-3(b)).

ROC curves were used to determine the sensitivity and specificity of the three genes individually and combined in a biomarker panel (Figure 4). RASSF1A methylation in the examined tissue samples had a sensitivity of 52%, a specificity of 100%, and an AUC of 0.73 (95% CI, 0.57–0.88). B4GALT1 methylation exhibited a sensitivity of 52%, a specificity of 100%, and an AUC of 0.75 (95% CI, 0.71–0.89). For SSBP2, the sensitivity was 38%, specificity was 100%, and the AUC was 0.58 (95% CI, 0.40–0.75) (Table 2).
Epigenetic lesions in DNA without mutations in the coding regions have been shown to be common phenomena in the pathogenesis of a wide range of cancers, especially the methylation-mediated silencing of tumor suppressor genes such as VHL, p16INK4a, E-cadherin, hMLH1, BRCA1, and LKB1 [25, 26]. Moreover, promoter hypermethylation has been linked with a large number of genes involved in HCC including RASSF1A, APC, GSTP1, SOX17, and RIZ1 [27–29]. Analysis of tissue specimens has revealed that DNA methylation alterations, the best-understood epigenomic biomarker, play a part in a multistage carcinogenic procedure leading to HCC [27].

Differential methylation has been identified from the early precancerous stages, in association with inflammation and/or persistent infection with HBV or HCV seen in chronic hepatitis or liver cirrhosis to HCC lesions [30]. In addition, concordance of hypermethylation patterns has been shown in matching tissue and plasma DNA from HCC patients [31]. Furthermore, aberrant methylation of a panel of three genes has been reported in serum DNA, 1 to 9 years before clinical diagnosis of HCC [32]. Therefore, unraveling epigenetic alterations in HCC opened up possibilities for discovering new biomarkers for detection and prognosis [9].

By using a study principle that combines promoter-wide and gene-specific methylation platforms that interrogate the promoter region, we were able to distinguish HCC from non-HCC tissue. Our group and others have previously shown that analytical platforms, which quantified global DNA methylation in repetitive regions of the genome, could also distinguish between HCC and non-HCC tissue [33, 34]. DNA methylation alterations in either the promoter or the repetitive elements regions of the genome may therefore serve as useful molecular biomarkers for screening and clinical management for HCC.

The primary goal of our study was to test whether a small sample size is sufficient to provide information on methylation-related studies by using Illumina BeadChip assays and the Nimblegen oligonucleotide arrays. Our discovery set, although including a limited number of samples, was able to identify genes differentially methylated in HCC when compared to normal samples. Among them, there were genes previously reported as also genes with a known role in HCC and other cancer types. To further validate our findings and the power of a genome-wide analysis based on a small sample size, we generated a list of hypermethylated genes in HCC. We ranked the list based on both the frequency in which the genes had been identified in different studies and also in the methylation arrays we used.

RASSF1A, SSBP2, and B4GALT1 were selected for further study. Promoter hypermethylation of RASSF1A, SSBP2, and B4GALT1 quantified by qMSP had a sensitivity ranging from 38% to 52%, a specificity of 100%, and an AUC from 0.58 to 0.75. A panel combining these genes with HCC risk factors had a sensitivity of 87%, a specificity of 100%, and an AUC of 0.91.

As our knowledge of the HCC epigenome increases, new therapeutic and clinical management strategies may be
Figure 3: Quantitative MSP results of hepatocellular carcinoma samples and adjacent normal liver samples that were bisulfite treated to examine the promoter methylation status of RASSF1A, B4GALT1, and SSBP2. Scatter plots of quantitative MSP analysis of candidate gene promoters. Twenty-two adjacent normal liver tissue samples and 27 hepatocellular carcinoma samples were tested for methylation for each of the three genes by quantitative MSP. The relative level of methylated DNA for each gene in each sample was determined as a ratio of MSP for the amplified gene to ACTB and then multiplied by 100 for easier tabulation (average value of duplicates of gene of interest/average value of duplicates of ACTB × 100). The samples were categorized as unmethylated or methylated based on detection of methylation above a threshold set for each gene. This threshold was determined by analyzing the levels and distribution of methylation, if any, in normal, age-matched tissues.

Figure 4: ROC curves for a panel of the three genes RASSF1A, B4GALT1, and SSBP2, individually, (a) and after adjusting a logistic regression model with HCC risk factors: age, gender, ethnicity, and etiology. (b).

developed and new serum-based screening or needle biopsy-based diagnostic tools may become available for subgroups at risk for HCC. The pace of DNA methylation translational research is expected to increase exponentially due to the rapid advancement of high-throughput promoter-wide technologies, such as microarray and next-generation sequencing, as well as the advent of user-friendly commercial kits for methylation enrichment [35]. Restoring epigenetically altered pathways is a current research endeavor that will probably lead to the development of new therapeutic tools with translational advantages in malignancies. We are advancing into a new era of individualized molecular medicine, which will allow successful bidirectional interactions between the laboratory bench and patient therapies, based on a better understanding of the genetic and epigenetic mechanisms of human cancers, including HCC.

The aim of this paper was not to provide robust conclusions about specific biomarkers but rather to demonstrate that discrimination between HCC and non-HCC liver tissue using currently available technologies that quantify promoter-wide and gene-specific DNA methylation alterations is feasible. The usefulness of the markers showcased in this paper still needs to be determined in follow-up studies. However, the technological platforms we have used in this project can have an immediate impact on clinical and biomarker development studies.

5. Conclusion
Promoter-wide microarray technologies may be used to identify methylation patterns that distinguish between HCC and non-HCC tissue. These technologies are well suited
for personalized diagnostics and clinical management. As utilization costs of microarrays decrease, population-based studies may also consider using custom-made microarrays to examine large numbers of participants in prevention and early detection studies. Furthermore, we have also shown how qMSP analyses can be used for fast, accurate, and cost-effective high-throughput validation of methylation frequencies in a large number of samples. There is a potential to test the arising genes’ lists to detect biomarkers for early HCC detection in bodily fluids such as plasma, serum, or urine and provide a noninvasive method to clinicians to stratify patients of higher risk for HCC. As the field of translational epigenomics moves forward, clinical tests using these technologies will be warranted to determine their usefulness and reliability in novel screening and clinical management approaches for HCC.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This research was supported in part by the following Grant Awards: NCI U01CA084986 and K01CA164092. The authors want to thank Regina Santella for providing normal liver and hepatocellular carcinoma samples and Rafael Irizarry for his help and supervision in bioinformatics and biostatistics.

References

[1] N. Wong, W.-C. Lam, P. B.-S. Lai, E. Pang, W.-Y. Lau, and P. J. Johnson, “Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma,” American Journal of Pathology, vol. 159, no. 2, pp. 465–471, 2001.

[2] Y. Saito, Y. Kanai, M. Sakamoto, H. Saito, H. Ishii, and S. Hirohashi, “Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 15, pp. 10060–10065, 2002.

[3] T. Moribe, N. Iizuka, T. Miura et al., “Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma,” International Journal of Cancer, vol. 125, no. 2, pp. 388–397, 2009.

[4] S. H. Shin, B.-H. Kim, J.-J. Jang, K. S. Suh, and G. H. Kang, “Identification of novel methylation markers in hepatocellular carcinoma using a methylation array,” Journal of Korean Medical Science, vol. 25, no. 8, pp. 1152–1159, 2010.

[5] S. H. Tang, D. H. Yang, W. Huang, H. K. Zhou, X. H. Lu, and G. Ye, “Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population,” Clinical Cancer Research, vol. 12, no. 14, pp. 4171–4177, 2006.

[6] B. Cho, H. Lee, S. W. Jeong et al., “Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma,” Biochemical and Biophysical Research Communications, vol. 307, no. 1, pp. 52–63, 2003.

[7] W. Gao, Y. Kondo, L. Shen et al., “Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas,” Carcinogenesis, vol. 29, no. 10, pp. 1901–1910, 2008.

[8] Y.-B. Deng, G. Nagaie, Y. Midorikawa et al., “Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma,” Cancer Science, vol. 101, no. 6, pp. 1501–1510, 2010.

[9] H. Hernandez-Vargas, M.-P. Lambert, F. Le Calvez-Kelm et al., “Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors,” PLoS ONE, vol. 5, no. 3, Article ID e9749, 2010.

[10] D. F. Calvisi, S. Ladu, A. Gorden et al., “Ubiquitous activation of Ras and Jak/Stat pathways in human HCC,” Gastroenterology, vol. 130, no. 4, pp. II17–II28, 2006.

[11] E. L. Sceusi, D. S. Loose, and C. J. Wray, “Clinical implications of DNA methylation in hepatocellular carcinoma,” HPB, vol. 13, no. 6, pp. 369–376, 2011.

[12] J. Shen, S. Wang, Y. J. Zhang et al., “Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips,” Epigenetics, vol. 8, no. 1, pp. 34–43, 2013.

[13] M. O. Hoque, C.-C. R. Lee, P. Cairns, M. Schoenberg, and D. Sidransky, “Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis,” Cancer Research, vol. 63, no. 9, pp. 2216–2222, 2003.

[14] M. O. Hoque, O. Topaloglu, S. Begum et al., “Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects,” Journal of Clinical Oncology, vol. 23, no. 27, pp. 6569–6575, 2005.

[15] P. C. Scacheri, G. E. Crawford, and S. Davis, “Statistics for ChiP-chip and DNase hypersensitivity experiments on NimbleGen arrays,” Methods in Enzymology, vol. 411, pp. 270–282, 2006.

[16] Y.-C. Fang, H.-C. Huang, and H.-F. Juan, “MethylInfoText: associated gene methylation and cancer information from text mining,” BMC Bioinformatics, vol. 9, p. 22, 2008.

[17] X. He, S. Chang, J. Zhang et al., “MethyCancer: the database of human DNA methylation and cancer,” Nucleic Acids Research, vol. 36, no. 1, pp. D836–D841, 2008.

[18] Y. Huang, X. Chang, J. Lee et al., “Cigarette smoke induces promoter methylation of single-stranded DNA-binding protein 2 in human esophageal squamous cell carcinoma,” International Journal of Cancer, vol. 128, no. 10, pp. 2261–2273, 2011.

[19] G. B. A. Wisman, E. R. Nijhuis, M. O. Hoque et al., “Assessment of gene promoter hypermethylation for detection of cervical neoplasia,” International Journal of Cancer, vol. 119, no. 8, pp. 1908–1914, 2006.

[20] M. Brait, L. Maldonado, M. G. Noordhuis et al., “Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression,” PLoS ONE, vol. 8, no. 9, Article ID e70878, 2013.

[21] M. Brait, M. Loyo, E. Rosenbaum et al., “Correlation between BRAF mutation and promoter methylation of TIMP3, RAR-beta2 and RASSF1A in thyroid cancer,” Epigenetics, vol. 7, no. 7, pp. 710–719, 2012.

[22] F. X. Bosch, J. Ribes, M. Diaz, and R. Cléries, “Primary liver cancer: worldwide incidence and trends,” Gastroenterology, vol. 127, no. 5, supplement 1, pp. S5–S16, 2004.
B. K. Edwards, E. Ward, B. A. Kohler et al., “Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates,” *Cancer*, vol. 116, no. 3, pp. 544–573, 2010.

M. B. Thomas, D. Jaffe, M. M. Choti et al., “Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting,” *Journal of Clinical Oncology*, vol. 28, no. 25, pp. 3994–4005, 2010.

M. Esteller, “CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future,” *Oncogene*, vol. 21, no. 35, pp. 5427–5440, 2002.

P. A. Jones and S. B. Baylin, “The fundamental role of epigenetic events in cancer,” *Nature Reviews Genetics*, vol. 3, no. 6, pp. 415–428, 2002.

E. J. Formeister, M. Tsuchiya, H. Fujii, S. Shpyleva, I. P. Pogribny, and I. Rusyn, “Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma,” *Mutation Research*, vol. 692, no. 1-2, pp. 26–33, 2010.

Y. Jia, Y. Yang, S. Liu, J. G. Herman, F. Lu, and M. Guo, “SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma,” *Epigenetics*, vol. 5, no. 8, pp. 743–749, 2010.

A. Csepregi, M. P. A. Ebert, C. Röcken et al., “Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma,” *BMC Cancer*, vol. 10, Article ID 3171471, 2010.

Y. Kanai, A.-M. Hui, L. Sun et al., “DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis,” *Hepatology*, vol. 29, no. 3, pp. 703–709, 1999.

P. Iyer, A.-R. Zekri, C.-W. Hung et al., “Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients,” *Experimental and Molecular Pathology*, vol. 88, no. 1, pp. 107–111, 2010.

Y.-J. Zhang, H.-C. Wu, J. Shen et al., “Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA,” *Clinical Cancer Research*, vol. 13, no. 8, pp. 2378–2384, 2007.

R. Guerrero-Preston, R. M. Santella, A. Blanco, M. Desai, M. Berdasco, and M. Fraga, “Global DNA hypomethylation in liver cancer cases and controls: a phase I preclinical biomarker development study,” *Epigenetics*, vol. 2, no. 4, pp. 223–226, 2007.

C.-H. Lin, S.-Y. Hsieh, I.-S. Sheen et al., “Genome-wide hypomethylation in hepatocellular carcinogenesis,” *Cancer Research*, vol. 61, no. 10, pp. 4238–4243, 2001.

M. M. Suzuki and A. Bird, “DNA methylation landscapes: provocative insights from epigenomics,” *Nature Reviews Genetics*, vol. 9, no. 6, pp. 465–476, 2008.